Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > According to Bloomberg...

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Sep 11, 2022 4:31pm

152 Views

Post# 34955340

RE:RE:According to Bloomberg...

I will believe it when I see it. I have to wonder if they lost or fired the former Trogarzo lead as this is not optimal timing to be hiring this close to th IV Push approval.

scarlet1967 wrote: Hopefully with launch of IV push/IM
Trogarzo's sales also gain some traction.

Check out this job at Theratechnologies Inc.:
https://www.linkedin.com/jobs/view/3260124383

SPCEO1 wrote: So, you already know to be suspicious since it is Bloomberg and the track record of their sales estimates is poor.

Egrifta sales seem to be doing reasonably well. In dollar terms, sales were at an all-time high in August, but that was largely due to price increases as unit sales in August were only the highest since 2020. While the trend in Egrifta sales seems somwhat hopeful, I still am not expecting some blowout to the upside type numbers for Q3. I am just hoping they will be good enough to keep the company from further cutting their 2022 sales guidance.

Trogarzo sales look flattish for the quarter and really for the last two years.

WIth Egrifta likely having close to 95% gross margins and Trogarzo about half that, I am glad Egrifta is the drug doing better.

Also, on the revenue criterion, they will now qualify for that aspect of the second round of the debt deal. If they can get the F8 filed, then the remainder of the convert will be taken care of.